1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009.
|
2
|
Weiss SW and Enzinger FM: Malignant
fibrous histiocytoma: an analysis of 200 cases. Cancer.
41:2250–2266. 1978.
|
3
|
Grimer RJ, Gosheger G, Taminiau A, et al:
Dedifferentiated chondrosarcoma: prognostic factors and outcome
from a European group. Eur J Cancer. 43:2060–2065. 2007.
|
4
|
Cores EP, Holland JF, Wang JJ and Sinks
LF: Doxorubicin in disseminated osteosarcoma. JAMA. 221:1132–1138.
1972.
|
5
|
Jaffe N, Paed D, Farber S, et al:
Favorable response of metastatic osteogenic sarcoma to pulse
high-dose methotrexate with citrovorum rescue and radiation
therapy. Cancer. 31:1367–1373. 1973.
|
6
|
Ochs JJ, Freeman AI, Douglass HO Jr, Higby
DS, Mindell ER and Sinks LF: cis-Dichlorodiammineplatinum (II) in
advanced osteogenic sarcoma. Cancer Treat Rep. 62:239–245.
1978.
|
7
|
Link MP, Goorin AM, Miser AW, et al: The
effect of adjuvant chemotherapy on relapse-free survival in
patients with osteosarcoma of the extremity. N Eng J Med.
314:1600–1606. 1986.
|
8
|
Eilber F, Giuliano A, Eckardt J, Patterson
K, Moseley S and Goodnight J: Adjuvant chemotherapy for
osteosarcoma: a randomized prospective trial. J Clin Oncol.
5:21–26. 1987.
|
9
|
Miser JS, Kinsella TJ, Triche TJ, et al:
Ifosfamide with mesna uroprotection and etoposide: an effective
regimen in the treatment of recurrent sarcomas and other tumors of
children and young adults. J Clin Oncol. 5:1191–1198. 1987.
|
10
|
Goorin AM, Harris MB, Bernstein M, et al:
Phase II/III trial of etoposide and high-dose ifosfamide in newly
diagnosed metastatic osteosarcoma: a pediatric oncology group
trial. J Clin Oncol. 20:426–433. 2002.
|
11
|
Ferrari S, Ruggieri P, Cefalo G, et al:
Neoadjuvant chemotherapy with methotrexate, cisplatin, and
doxorubicin with or without ifosfamide in nonmetastatic
osteosarcoma of the extremity: an Italian sarcoma group trial
ISG/OS-1. J Clin Oncol. 30:2112–2118. 2012.
|
12
|
Song WS, Kong CB, Jeon DG, et al:
Prognosis of extremity osteosarcoma in patients aged 40–60 years: a
cohort/case controlled study at a single institute. Eur J Surg
Oncol. 36:483–488. 2010.
|
13
|
Bramwell VH, Steward WP, Nooij M, et al:
Neoadjuvant chemotherapy with doxorubicin and cisplatin in
malignant fibrous histiocytoma of bone: A European Osteosarcoma
Intergroup study. J Clin Oncol. 17:3260–3269. 1999.
|
14
|
Woll PJ, Reichardt P, Le Cesne A, et al:
EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical
Trials Group Sarcoma Disease Site Committee: Adjuvant chemotherapy
with doxorubicin, ifosfamide, and lenograstim for resected
soft-tissue sarcoma (EORTC 62931): a multicentre randomised
controlled trial. Lancet Oncol. 13:1045–1054. 2012.
|
15
|
Frustaci S, Gherlinzoni F, De Paoli A, et
al: Adjuvant chemotherapy for adult soft tissue sarcomas of the
extremities and girdles: results of the Italian randomized
cooperative trial. J Clin Oncol. 19:1238–1247. 2001.
|
16
|
Edge SB, Byrd DR, Compton CC, et al: Bone.
AJCC Cancer Staging Manual. 7th edition. New York, Springer; New
York, NY: pp. 281–290. 2010
|
17
|
National Cancer Institute. National Cancer
Institute Common Toxicity Criteria version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/.
Accessed September 10, 2013
|
18
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
|
19
|
Grimer RJ, Cannon SR, Taminiau AM, et al:
Osteosarcoma over the age of forty. Eur J Cancer. 39:157–163.
2003.
|
20
|
Nishida Y, Isu K, Ueda T, et al:
Osteosarcoma in the elderly over 60 years: a multicenter study by
the Japanese Musculoskeletal Oncology Group. J Sur Oncol.
100:48–54. 2009.
|
21
|
Comandone A, Bretti S, Bertetto O, Oliva
C, Bergnolo P and Bumma C: Low dose adriamycin and ifosfamide in
the treatment of advanced adult soft tissue sarcomas. Anticancer
Res. 20:2077–2080. 2000.
|
22
|
Urakawa H, Tsukushi S, Tsurudome I, et al:
Metastasis of osteosarcoma to stomach made clinically evident by
hematemesis: a case report. World J Surg Oncol. 11:482013.
|
23
|
Longhi A, Macchiagodena M, Vitali G and
Bacci G: Fertility in male patients treated with neoadjuvant
chemotherapy for osteosarcoma. J Pediatr Hematol/Oncol. 25:292–296.
2003.
|
24
|
Bacci G, Ferrari S, Bertoni F, et al:
Long-term outcome for patients with nonmetastatic osteosarcoma of
the extremity treated at the istituto ortopedico rizzoli according
to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an
updated report. J Clin Oncol. 18:4016–4027. 2000.
|
25
|
Bacci G, Ferrari S, Mercuri M, et al:
Neoadjuvant chemotherapy for osteosarcoma of the extremities in
patients aged 41–60 years: outcome in 34 cases treated with
adriamycin, cisplatinum and ifosfamide between 1984 and 1999. Acta
Orthop. 78:377–384. 2007.
|
26
|
Manoso MW, Healey JH, Boland PJ, et al: De
novo osteogenic sarcoma in patients older than forty: benefit of
multimodality therapy. Clin Orthop Relat Res. 438:110–115.
2005.
|